Romanian T2DM patients exhibit high residual cardiometabolic risk despite frequent biguanide, SGLT2i, and GLP-1 RA use
Real-World Pharmacological Patterns and Residual Cardiometabolic Risk in Patients with Type 2 Diabetes in Romania.
Abstract
Romanian T2DM patients frequently use biguanides (53%), SGLT2 inhibitors (44.8%), and GLP-1 RAs (15.5%), yet exhibit substantial residual cardiometabolic risk.
